Table 1. Four Clinical Phase III Randomized Controlled Trials That Compared ICIs to Sunitinib.
| Checkmate 214 | IMmotion 151 | KEYNOTE 426 | JAVELIN renal 101 | |
|---|---|---|---|---|
| Drugs compared | Ipilimumab/nivolumab vs. sunitinib | Atezolizumab/bevacizumab vs. sunitinib | Axitinib/pembrolizumab vs. sunitinib | Axitinib/avelumab vs. sunitinib |
| N | 60 vs. 52 | 68 vs. 74 | 51 vs. 54 | 47 vs. 61 |
| ORR, % | 56.7 vs. 19.2 | 49 vs. 14 | 58.8 vs. 31.5 | 46.8 vs. 21.3 |
| CR, % | 18.3 vs. 0 | 10 vs. 3 | NR | NR |
| PFS, months | 8.4 vs. 4.9 | 8.3 vs. 5.3 | NR | 7.4 vs. 4.0 |
| OS | Median OS: 31.2 vs. 13.6 months | Median OS: 21.7 vs. 15.4 months | 12 months OS: 83.4% vs. 79.5% | 12 months OS: 83% vs. 67% |
N: number of subjects with sRCC; ORR: objective response rate; CR: complete response rate; PFS: progression-free survival; OS: overall survival; NR: not reported; ICI: immune checkpoint inhibitor; sRCC: sarcomatoid renal cell carcinoma.